Bavarian Nordic Presents Combination Immunotherapy Data of PROSTVAC plus Ipilimumab at the AACR Annual Meeting 2014

KVISTGAARD, Denmark, April 7, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that updated data from an NCI sponsored combination study of Bavarian Nordic's active immunotherapy candidate PROSTVAC and ipilimumab will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego on Wednesday, April 9, 2014. The data highlights the potential synergy of combining PROSTVAC with an immune checkpoint inhibitor. Promising results showing clinical evidence from this phase 1 trial combining PROSTVAC plus ipilimumab were previously published in The Lancet Oncology. The reported median overall survival was 34.4 months in men with metastatic prostate cancer, and the combination therapy was well-tolerated. The presentation at the AACR conference will show hypothesis-generating data correlating immune outcomes with overall survival. These data provide rationale for prospectively evaluating these potential immune correlates of clinical benefit from combining PROSTVAC and immune checkpoint blockade in follow-on clinical studies. The senior author for the presentation as a poster is Jeffrey Schlom, Ph.D., Chief, Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH. The presentation will take place on Wednesday, April 9, 2014 from 8:00 AM -12:00 PM PDT. An abstract entitled: "A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: Immune correlates" is available online at James B. Breitmeyer, President of the Cancer Immunotherapy Division of Bavarian Nordic, said: "We are excited to continue exploration of the potential synergy in clinical response from combination therapy with PROSTVAC and immune checkpoint inhibitors, including ipilimumab, as well as a number of other anticancer agents." Asger Aamund Chairman of the Board Contacts Anders Hedegaard, President & CEO. Phone +45 23 20 30 64 About Bavarian Nordic Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX®. Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY. For more information, visit Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. 201404uk: This announcement is distributed by GlobeNewswire on behalf of GlobeNewswire clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Bavarian Nordic A/S via GlobeNewswire [HUG#1775088]